Remifentanil in Children With Obstructive Sleep Apnea

• Status: Completed
• Trial end date: 2017-10-31
• Target enrollment: 0
• Participant gender: All

Summary

This investigation tested the hypothesis that children with obstructive sleep apnea have an increased pharmacodynamic sensitivity to the miotic and respiratory depressant effects of the prototypic μ-opioid agonist remifentanil.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Remifentanil

Criteria

OSA Group:

Inclusion Criteria:

• 8-14 years old

• ASA physical status 1 or 2

• undergoing tonsillectomy or tonsillectomy and adenoidectomy for known obstructive sleep apnea

Exclusion Criteria:

• Inability to cooperate with study requirements (IV placement, sitting quietly, wearing goggles, etc.)

Control (Non-OSA) Group:

Inclusion Criteria:

• 8-14 years old

• ASA physical status 1 or 2

• no known obstructive sleep apnea presenting for any procedure requiring general anesthtic

Exclusion Criteria:

• Inability to cooperate with study requirements (IV placement, sitting quietly, wearing goggles, etc.)